[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368005-105":59,"doc-detail-368005-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","chemoresistome-mapping-in-individual-breast-cancer-patients-unravels-diversity-in-dynamic-transcriptional-adaptation","Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation","","Nongenetic adaptive resistance to chemotherapy emerges as a key mechanism in tumor survival through transcriptional rewiring. The study integrates longitudinal transcriptomics with temporal pattern analysis to define patient-specific mechanisms of acquired breast cancer resistance using matched tumor biopsies from neoadjuvant-treated patients. Resistance-associated genes are dysregulated before therapy, indicating a preexisting drug-tolerant state. Individual patients follow distinct gene and pathway routes that converge on limited functional modules. The work proposes personalized chemoresistome maps to reveal vulnerabilities and guide therapy.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/chemoresistome-mapping-in-individual-breast-cancer-patients-unravels-diversity-in-dynamic-transcriptional-adaptation/368005/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/chemoresistome-mapping-in-individual-breast-cancer-patients-unravels-diversity-in-dynamic-transcriptional-adaptation/368005.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What mechanism of chemotherapy resistance does the study focus on?","Question",{"text":112,"@type":113},"The study focuses on nongenetic adaptive resistance driven by transcriptional rewiring, which supports tumor survival during chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patient-specific resistance mechanisms investigated?",{"text":117,"@type":113},"By combining longitudinal transcriptomics with temporal pattern analysis using matched tumor biopsies taken before treatment, after treatment, and from adjacent normal tissue.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the study suggest about drug-tolerant states in primary tumors?",{"text":121,"@type":113},"Resistance-associated genes are already dysregulated in primary tumors, indicating a preexisting drug-tolerant state before chemotherapy.",{"name":123,"@type":110,"acceptedAnswer":124},"What are “chemoresistome maps” intended to do?",{"text":125,"@type":113},"They are proposed as individualized maps that can identify cancer vulnerabilities and inform personalized therapeutic strategies to overcome or prevent resistance.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},368005,1790486386,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":31,"preview_page_count":19,"preview_urls":148},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation  \nMaya Dadiani 1,2 , Gilgi Friedlander3, Gili Perry 1, Nora Balint-Lahat4, Shlomit Gilad5, Dana Morzaev-Sulzbach 1, Anjana Shenoy6, Noa Bossel Ben-Moshe8, Anya Pavlovsky4,  \nRinat Bernstein-Molho6,9,10, Eytan Domany8, Iris Barshack4,6, Tamar Geiger6,7, Bella Kaufman6,10,† and Einav Nili Gal-Yam 10,11  \n1 Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel  \n2 The Nehemia Rubin Excellence in Biomedical Research, The TELEM Program, Ramat Gen, Israel  \n3 Mantoux Bioinformatics Institute, The Nancy & Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel  \n4 Pathology Institute, Sheba Medical Center, Ramat Gan, Israel  \n5 The Nancy & Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel  \n6 Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel  \n7 Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel  \n8 Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel  \n9 The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center, Ramat Gan, Israel  \n10 Oncology Institute, Sheba Medical Center, Ramat Gan, Israel  \n11 The Dr. Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel  \nKeywords  \nbreast cancer; chemotherapy; resistance; transcriptional adaptation  \nCorrespondence  \nM. Dadiani, Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, 5262100, Israel [E-mail:](E-mail: maya.dadiani@sheba.health.gov.il)[ maya.dadiani@sheba.health.gov.il](E-mail: maya.dadiani@sheba.health.gov.il)and  \nE. N. Gal-Yam, The Oncology Institute, Sheba Medical Center, Tel-Hashomer, Ramat Gan, 5262100, Israel  \nE-mail: [Einav.NiliGalYam@sheba.health.gov.il](Einav.NiliGalYam@sheba.health.gov.il)[ ](Einav.NiliGalYam@sheba.health.gov.il)†Deceased.  \n(Received 30 June 2024, revised 18  \nDecember 2024, accepted 17 March 2025, available online 28 April 2025)  \ndoi:10 . 1002/1878-0261 .70030  \nNongenetic adaptive resistance to chemotherapy, driven by transcriptional rewiring, is emerging as a signiﬁcant mechanism in tumor survival. In this study we combined longitudinal transcriptomics with temporal pattern analysis to investigate patient-speciﬁc mechanisms underlying acquired resistance in breast cancer. Matched tumor biopsies (pretreatment, posttreatment, and adjacent normal) were collected from breast cancer patients who received neoadjuvant chemotherapy. Transcriptomes were analyzed by longitudinal gene-pattern classiﬁcation to track patient-speciﬁc gene expression alterations that occur during treatment. Our ﬁndings reveal that resistance-associated genes were already dysregulated in primary tumors, suggesting the presence of a preexisting drug-tolerant state. While each patient displayed unique resistance-associated gene rewiring, these alterations converged into a limited number of dysregulated functional modules. Notably, patients receiving the same treatment exhibited distinct rewiring of genes and pathways, revealing parallel, individualized routes to resistance. In conclusion, we propose that tumor cells survive chemotherapy by sustaining or amplifying a preexisting drug-tolerant state that circumvents drug action. We suggest that individualized “chemoresistome maps” could identify cancer vulnerabilities and inform personalized therapeutic strategies to overcome or prevent resistance.  \nAbbreviations  \nADC, antibody-drug-conjugates; ECM, extracellular matrix; FFPE, formalin-ﬁxed parafﬁn-embedded; HR+, hormone receptor positive; IRB, institutional review board; MP, Miller–Payne; NAT, neoadjuvant treatment; NBR, normal breast tissue; RCB, residual cancer burden; TNBC, triple negative breast cancer; VST, variance stabilizing transformation.  \nMolecular Oncology 19 (2025) 3665–3684 ª 2","cbCailz19pa63HTL","https://ap.wps.com/l/cbCailz19pa63HTL","pdf",9560836,"English","# Introduction\n## Rationale for studying adaptive (non-genetic) resistance\n# Methods and study design\n## Longitudinal transcriptomics and temporal pattern analysis\n# Key findings\n## Preexisting drug-tolerant state and functional module convergence\n## Individualized routes to resistance under the same treatment\n# Conclusions and implications\n## Chemoresistome maps for personalized therapeutic strategies","[{\"question\":\"What mechanism of chemotherapy resistance does the study focus on?\",\"answer\":\"The study focuses on nongenetic adaptive resistance driven by transcriptional rewiring, which supports tumor survival during chemotherapy.\"},{\"question\":\"How were patient-specific resistance mechanisms investigated?\",\"answer\":\"By combining longitudinal transcriptomics with temporal pattern analysis using matched tumor biopsies taken before treatment, after treatment, and from adjacent normal tissue.\"},{\"question\":\"What does the study suggest about drug-tolerant states in primary tumors?\",\"answer\":\"Resistance-associated genes are already dysregulated in primary tumors, indicating a preexisting drug-tolerant state before chemotherapy.\"},{\"question\":\"What are “chemoresistome maps” intended to do?\",\"answer\":\"They are proposed as individualized maps that can identify cancer vulnerabilities and inform personalized therapeutic strategies to overcome or prevent resistance.\"}]","Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation | PDF",1790174292,[149,153,157,161],{"page_no":8,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c0cfc83b9ad39687508d8bc34d6b2ed.webp",983,1291,{"page_no":14,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25791567b053a94c9d04f3a3cb13463b.webp",982,1290,{"page_no":81,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9276ac70c8699c3b0cf7e80e88d69ea8.webp",981,1289,{"page_no":19,"url":162,"width":163,"height":164},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd5e497339f98dad27f5c6fadde7e2d6.webp",980,1287]